Urvi M Parikh Selected Research

COVID-19

11/2023	SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback.
11/2023	Prospective Assessment of Humoral and Cellular Immune Responses to a Third COVID-19 mRNA Vaccine Dose Among Immunocompromised Individuals.
10/2023	Early antiviral CD4 and CD8 T cell responses are associated with upper respiratory tract clearance of SARS-CoV-2.
1/2023	Rapid determination of SARS-CoV-2 antibody neutralization titer using Bio-Rad Bio-Plex correlates strongly with pseudovirus-determined neutralization titer.
12/2022	Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses.
11/2022	Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19.
11/2022	Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
1/2022	Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS).
9/2021	Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Urvi M Parikh Research Topics

Disease

11	Infections 10/2023 - 03/2014
9	COVID-19 11/2023 - 09/2021
6	HIV Infections (HIV Infection) 10/2022 - 02/2015
3	Breakthrough Infections 10/2022 - 03/2014
3	Acquired Immunodeficiency Syndrome (AIDS) 11/2015 - 08/2012
1	HIV Seropositivity 01/2024
1	Neoplasms (Cancer) 11/2023
1	Viremia 01/2023
1	Disease Progression 01/2019
1	Virus Diseases (Viral Diseases) 03/2014

Drug/Important Bio-Agent (IBA)

5	DapivirineIBA 01/2022 - 12/2016
4	RNA (Ribonucleic Acid)IBA 01/2024 - 01/2019
4	bamlanivimabIBA 11/2023 - 09/2021
4	Tenofovir (Viread)FDA Link 01/2022 - 02/2015
3	Emtricitabine (Emtriva)FDA Link 01/2022 - 02/2015
3	RacivirIBA 01/2022 - 02/2015
2	Monoclonal AntibodiesIBA 11/2023 - 12/2022
2	Immunoglobulin G (IgG)IBA 11/2023 - 12/2022
2	Neutralizing AntibodiesIBA 10/2023 - 01/2023
2	Antiviral Agents (Antivirals)IBA 11/2022 - 09/2021
2	Contraceptive Agents (Contraceptives)IBA 10/2022 - 07/2015
2	Reverse Transcriptase InhibitorsIBA 01/2019 - 03/2014
2	Anti-Infective Agents (Microbicides)IBA 01/2019 - 03/2014
1	EpitopesIBA 11/2023
1	Therapeutic UsesIBA 11/2023
1	Messenger RNA (mRNA)IBA 11/2023
1	mRNA VaccinesIBA 11/2023
1	Viral RNAIBA 10/2023
1	islatravirIBA 01/2022
1	FumaratesIBA 01/2022
1	Broadly Neutralizing AntibodiesIBA 01/2022
1	VaccinesIBA 01/2022
1	cabotegravirIBA 01/2022
1	Anti-Retroviral Agents (Antiretroviral Agents)IBA 01/2022
1	NucleosidesIBA 01/2019
1	AntigensIBA 01/2017
1	Rilpivirine (TMC-278)IBA 03/2016
1	Vaginal Creams, Foams, and Jellies (Vaginal Tablet)IBA 02/2015
1	Raltegravir Potassium FDA Link 03/2014
1	Integrase InhibitorsIBA 03/2014

Therapy/Procedure

5	Therapeutics 01/2023 - 08/2012
5	Injections 10/2022 - 07/2015
4	Female Contraceptive Devices (Vaginal Ring) 01/2021 - 12/2016
2	Art Therapy 01/2019 - 11/2015
1	Investigational Therapies (Experimental Therapy) 11/2022
1	Contraception (Birth Control) 07/2015